Elutia Inc. (ELUT)
NASDAQ: ELUT · Real-Time Price · USD
0.8907
-0.0094 (-1.04%)
At close: Oct 17, 2025, 4:00 PM EDT
0.9000
+0.0093 (1.04%)
After-hours: Oct 17, 2025, 7:07 PM EDT
Elutia Revenue
Elutia had revenue of $6.26M in the quarter ending June 30, 2025, a decrease of -0.45%. This brings the company's revenue in the last twelve months to $23.68M, down -5.22% year-over-year. In the year 2024, Elutia had annual revenue of $24.38M, down -1.50%.
Revenue (ttm)
$23.68M
Revenue Growth
-5.22%
P/S Ratio
1.39
Revenue / Employee
$464,373
Employees
51
Market Cap
37.76M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 24.38M | -370.00K | -1.50% |
| Dec 31, 2023 | 24.75M | 896.00K | 3.76% |
| Dec 31, 2022 | 23.85M | -23.54M | -49.68% |
| Dec 31, 2021 | 47.39M | 4.71M | 11.03% |
| Dec 31, 2020 | 42.68M | -219.00K | -0.51% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ELUT News
- 4 days ago - Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21 - GlobeNewsWire
- 8 days ago - Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors - GlobeNewsWire
- 17 days ago - Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million - GlobeNewsWire
- 4 weeks ago - Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation - GlobeNewsWire
- 5 weeks ago - Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million - GlobeNewsWire
- 6 weeks ago - Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange - GlobeNewsWire
- 7 weeks ago - Elutia to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Elutia Inc. (ELUT) Q2 2025 Earnings Call Transcript - Seeking Alpha